Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
BMS’s Plans For Zeposia In Crohn’s Dubious Following Phase III Miss
Apr 01 2024
•
By
Joseph Haas
Bristol Myers Squibb missed its Phase III endpoint in Crohn's with Zeposia • Source: Shutterstock
More from Clinical Trials
More from R&D